BPC-157 has been reported to accelerate repair endpoints in rodent tendon, ligament, and gastrointestinal injury models.
What is not established
No adequate human efficacy trials exist. Findings are concentrated within a limited number of research groups. Animal quantities do not translate to humans.
Supporting sources (3)
Phase 1 pilot study in healthy volunteers to assess the safety and pharmacokinetics of PCO-02, whose active ingredient is BPC-157
PharmaCotherapia d.o.o. · Not published · 2015 · n = 42
- Population
- Healthy volunteers, single site, Hospital Angeles, Tijuana
- Endpoint
- Safety and pharmacokinetics
- Route
- Oral
- Quantity as reported
- Single administrations of 1, 3 or 6 tablets, each containing 1 mg; the repeated-dose phase used 3 tablets every 8 hours
- Frequency
- Single, then every 8 hours
- Duration
- 2 weeks
Result. No results have been posted. The registry status is Unknown and the trial has not been published.
Adverse events. Not reported.
Limitations. This is the entire registered human record for BPC-157, and it is an oral formulation with no posted results. It is not evidence that injected BPC-157 works, and it is frequently cited as though it were.
Preclinical literature on BPC-157 and tendon, ligament, and gastrointestinal repair
Multiple research groups (predominantly Sikiric and colleagues) · Various preclinical journals · 2023
- Population
- Rodent injury models (tendon transection, ligament, colitis, and others)
- Endpoint
- Histological and functional repair endpoints in animal injury models
- Route
- Intraperitoneal, intragastric, and topical in animal models
- Quantity as reported
- Reported in animal models as µg/kg body weight — not translatable to humans
- Frequency
- Varies by model
Result. Consistent positive findings across rodent models. Reporting is heavily concentrated in a small number of research groups.
Adverse events. Not systematically characterised in humans.
Limitations. No adequate published human efficacy trials. Concentration of findings within a limited set of groups reduces independent replication. Animal dosing does not translate to human quantities.
Peptide therapeutics in musculoskeletal medicine: a review of the evidence
Multiple · American Journal of Sports Medicine · 2026
- Population
- Review of the published literature on peptides marketed for musculoskeletal use
- Endpoint
- State of the evidence for musculoskeletal indications
Result. Concludes that no clinical data support the use of GHK-Cu for musculoskeletal conditions, that CJC-1295 and ipamorelin synergy data is murine only, that tesamorelin has no supporting orthopaedic evidence, and that for the class generally the indications, amounts, frequency and duration of treatment remain unknown.
Adverse events. Not an outcome of the review.
Limitations. A narrative review, not a meta-analysis. It is catalogued because it is the most recent peer-reviewed statement of how thin this evidence base is, and because it is the counterweight to every vendor page that implies otherwise.
Last evidence review: 2026-08-23